文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.

作者信息

Rizzo Alessandro, Ricci Angela Dalia, Brandi Giovanni

机构信息

Department of Experimental, Diagnostic & Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, 40138, Italy.

出版信息

Future Oncol. 2021 Mar;17(7):755-757. doi: 10.2217/fon-2020-0986. Epub 2021 Jan 29.

DOI:10.2217/fon-2020-0986
PMID:33508960
Abstract
摘要

相似文献

[1]
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.

Future Oncol. 2021-3

[2]
Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.

Front Immunol. 2021

[3]
Pursuing efficacious systemic therapy for hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol. 2021-2

[4]
Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.

Medicine (Baltimore). 2021-6-25

[5]
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.

Front Immunol. 2021

[6]
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).

Gastroenterology. 2021-9

[7]
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.

Front Immunol. 2021

[8]
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.

Hepatology. 2021-7

[9]
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.

Lancet Oncol. 2021-7

[10]
Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.

Clin Liver Dis. 2020-11

引用本文的文献

[1]
Integrating Bulk and Single-Cell RNA Sequencing Data Reveals the Prognostic Significance of HOXC9-Related Immune Gene Signatures in Hepatocellular Carcinoma.

Onco Targets Ther. 2025-3-29

[2]
Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate.

Pathobiology. 2025

[3]
Unraveling the therapeutic potential of Calculus Bovis in liver cancer: A novel step for targeted cancer treatment.

World J Gastroenterol. 2025-1-21

[4]
Transarterial Chemoembolization Combined with Microwave Ablation in Elderly Patients with Recurrent Medium or Large Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2024-10-22

[5]
Advancements in nutritional diagnosis and support strategies during the perioperative period for patients with liver cancer.

World J Gastrointest Surg. 2024-8-27

[6]
Feasibility and Safety of the Clinical Outcomes of TACE Combined with Lenvatinib and PD-1 Blockades in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Exploratory Study.

Int J Gen Med. 2024-8-21

[7]
Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.

BMC Cancer. 2024-8-19

[8]
inhibits M2 tumor-associated macrophage polarization Wnt/β-catenin pathway modulation to suppress liver cancer.

World J Gastroenterol. 2024-8-7

[9]
Optimizing the resveratrol fragments for novel in silico hepatocellular carcinoma de novo drug design.

Sci Rep. 2024-7-28

[10]
Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation.

Cancer Commun (Lond). 2024-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索